COMMUNIQUÉS West-GlobeNewswire
-
scPharmaceuticals Inc. Announces Closing of Over-Allotment Option in its Initial Public Offering
29/11/2017 - 15:23 -
Cesca Therapeutics Inc. Announces Pricing of Public Offering of up to 900,000 shares of Common Stock
29/11/2017 - 15:07 -
NSS Labs Adds Dina Bruzek as Senior Vice President of Products
29/11/2017 - 15:00 -
International Stem Cell Corporation Doses 7th Patient in Clinical Trial for Parkinson's Disease
29/11/2017 - 14:30 -
Avid Bioservices Announces Appointment of Tracy Kinjerski as Vice President of Business Operations
29/11/2017 - 14:05 -
Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome
29/11/2017 - 14:05 -
Cancer Genetics Initiates Partnership to Reduce Alarmingly Increasing Cancer Mortality Rates in India
29/11/2017 - 14:02 -
PhaseBio Announces $15.6 Million in Funds to Support Clinical Advancement of Orphan Cardiovascular Pipeline
29/11/2017 - 14:00 -
Biotricity Recognizes Remote Monitoring is Key to Chronic Care Management
29/11/2017 - 14:00 -
ONC Health IT Certification Program Director Joins EHNAC as Ex Officio Commissioner
29/11/2017 - 14:00 -
CASMED to Present at the LD Micro Main Event Conference
29/11/2017 - 14:00 -
scPharmaceuticals Inc. Announces Closing of Initial Public Offering
29/11/2017 - 14:00 -
Zogenix to Participate in the Global Mizuho Investor Conference 2017
29/11/2017 - 14:00 -
Inovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
29/11/2017 - 14:00 -
Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)
29/11/2017 - 14:00 -
Cancer Genetics and Indian Cooperative Oncology Network (ICON) Collaborate to Reduce Alarmingly Increasing Cancer Mortality Rates
29/11/2017 - 14:00 -
Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
29/11/2017 - 13:55 -
A Personal Letter to the Shareholders from Michael T. Redman, CEO of Oncolix, Inc.
29/11/2017 - 13:30 -
U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals’ IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma
29/11/2017 - 13:30
Pages